Novel blood test shows promising accuracy for detection of early-stage pancreatic cancer
Click Here to Manage Email Alerts
A next-generation biomarker-based blood test demonstrated 98% specificity and 75% sensitivity in detecting stage I and II pancreatic ductal adenocarcinoma, according to a press release from the manufacturer.
The test, which achieved both primary and secondary endpoints during a model-development study, is more accurate than CA19-9, the biomarker typically used to detect pancreatic cancer, according to release.
The study included 481 blood samples — 133 from patients with stage I or II pancreatic ductal adenocarcinoma and 348 control samples that included patients at high-risk for hereditary and familial pancreatic cancer, diabetics, patients with benign pancreatic lesions, and healthy individuals.
The results of the model-development study confirm technical advancement over IMMray PanCan-d, Immunovia’s first-generation test. The new test includes high-performing protein biomarkers, making the test less reliant on CA19-9, which approximately 10% of patients and mostly patients of African descent do not produce.
The analysis of the new test included patients with low CA19-9 values.
“Pancreatic cancer is a brutal and lethal cancer,” Jeff Borcherding, CEO and president of Immunovia, said in the release. “People at risk for pancreatic cancer need a simple, fast and easy blood test to detect cancer early. We are very excited about the potential of our test to meet this need and increase survival rates for these patients.”
Immunovia is preparing a second phase of the model development study to conduct additional statistical analysis that will include patients at high-risk for pancreatic cancer.
Click Here to Manage Email Alerts